Winston-Salem, North Carolina Feb 05, 2008
Targacept, Inc. (Nasdaq: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics (TM), today announced that it will conduct a conference call and audio webcast at 5:00 p.m. EST on Tuesday, February 12, 2008 following the after-market release of its financial results for the fourth quarter and year ended December 31, 2007. J. Donald deBethizy, Ph.D., President and Chief Executive Officer, and Alan A. Musso, Vice President and Chief Financial Officer, will host the call, during which they will discuss Targacept’s financial results and provide an update on the company's product development programs and business activities.
A live webcast of the conference call will be accessible from the Investor Relations page of Targacept’s website, www.targacept.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on Targacept’s website for at least two weeks following the call.
The conference call may be accessed by dialing 800-901-5248 for domestic participants and 617-786-4512 for international callers (reference passcode 98002378). A replay of the conference call may be accessed at least through February 26, 2008 by dialing 888-286-8010 for domestic callers and 617-801-6888 for international callers (reference passcode 76617911).
About Targacept
Targacept, a clinical-stage biopharmaceutical company, is a world leader in the discovery and development of NNR Therapeutics (TM), a new class of drugs for the treatment of central nervous system diseases and disorders. Targacept’s product candidates selectively modulate neuronal nicotinic receptors that serve as key regulators of the nervous system to promote therapeutic effects and limit adverse side effects. Targacept has product candidates in clinical development for Alzheimer’s disease and cognitive deficits in schizophrenia, depression and anxiety disorders, and pain, as well as multiple preclinical programs. Targacept has ongoing strategic alliances with AstraZeneca and GlaxoSmithKline. Additional information is available at www.targacept.com.
Contacts:
Alan Musso, VP and CFO
Targacept, Inc.
Tel: (336) 480-2186
Email: alan.musso@targacept.com
Michelle Linn
Linnden Communications
Tel: (508) 362-3087
Email: michelle@linndencom.com